granted us patent for ceflatonin manufacture

Sydney - Friday - February 2: (RWE Australian Business News) -
ChemGenex Pharmaceuticals Ltd (ASX code: CXS) has been granted a United
States patent that protects the semi-synthetic production of
homoharringtonine (Ceflatonin) and its analogs, and the use of thse
compounds in a treatment of leukemia.
The US patent, entitled "Cephalotaxane Derivatives and Their
Processes of Preparation and Purification", provides ChemGenex and its
partner Stragen Pharma with a proprietary position until 2019 in the US.